PHS
PSNL icon

PFM Health Sciences’s Personalis PSNL Stock Holding History

PFM Health Sciences’s Portfolio PSNL Stock Details PSNL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-870,097
Closed -$5.54M – 108
2026
Q1 		$5.54M Buy
870,097
+64,280
+8% +$543K 0.51% 62
2025
Q4 		$6.41M Buy
+805,817
New +$7.05M 0.64% 49

Other funds holding PSNL

MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

PFM Health Sciences's PSNL Position: Q2 2026 in Review

PFM Health Sciences sold out of Personalis (PSNL) in Q2 2026, closing a stake of 870,097 shares — an estimated $5.54M sold.

PFM Health Sciences first reported a position in PSNL in Q4 2025 and held it in 2 quarters. The position peaked at $6.41M in Q4 2025. 159 funds tracked by Wall St. Rank hold PSNL as of Q2 2026.

  • PFM Health Sciences reported no remaining Personalis position as of Q2 2026 after selling out during the quarter.
  • PFM Health Sciences sold 870,097 Personalis shares in Q2 2026, an estimated $5.54M.
  • PFM Health Sciences first reported a position in Personalis in Q4 2025 and held it in 2 quarters.
  • PFM Health Sciences's Personalis position peaked at $6.41M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Personalis as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.